Clinical Trials
10 trialsNCT07359859 2026-05-27
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07566377 2026-05-14
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06996119 2026-05-11
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT06926595 2026-04-03
GVHD-PTCy
Milton S. Hershey Medical Center
Phase 2 Recruiting
NCT06799195 2025-12-15
PTCYGVHD
University of Nebraska
Phase 2 Recruiting
NCT04678401 2025-10-20
IS-free Treg HaploHCT
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06815003 2025-06-27
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
Phase 2 Recruiting
NCT06299462 2025-02-25
PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
Phase 1/2 Recruiting
NCT03852407 2022-10-12
HLA
University of Liege
Phase 2 Recruiting
NCT03818334 2019-02-01
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies
Hospital Israelita Albert Einstein
Phase 2/3 Recruiting